Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

William Hurlbut, a physician and ethicist, is best known as a member of the President’s Council on Bioethics. Though he has spoken out against the destruction of embryos for research purposes, he is nonetheless a supporter of ­embryonic-stem-cell research. He avoids what would otherwise be a terminal para­dox through a proposal that he calls “altered nuclear transfer,” or ANT. His goal: to create embryonic stem cells without destroying human embryos.

One of the most promising methods for creating embryonic stem cells is cloning: the nucleus of an egg cell is replaced by the nucleus of an adult cell, a process called somatic-cell nuclear transfer. The egg is then induced to divide, and the stem cells harvested from the resulting embryo are pluripotent, meaning they can form any sort of tissue in the body. But harvesting the stem cells destroys the embryo. By contrast, ANT (which has been shown to work in mice, if not humans) switches off vital genes–through alteration of the somatic-cell nucleus, the cytoplasm of the egg, or both–before the transfer takes place. Hurlbut says the resulting cell mass could not become an embryo but could produce pluripotent stem cells.

Hurlbut recently spoke with Michael Fitzgerald about ANT.

TR: What compelled you to come up with altered nuclear transfer?

William Hurlbut: When the President’s Council met [to debate the ethics of stem-cell research, in 2002], it was clear that both sides of this debate are promoting important positive goods: that on the one hand you have people trying to defend human dignity from its earliest stages, and on the other hand you have people trying to promote advances in science and medicine. And as I sat there and listened to this debate, I thought, “Isn’t there an answer to this? Isn’t there some third option, some way that both of these goals can be achieved?”

I thought of dermoid cysts, benign ovarian tumors that produce all the cell types, tissues, and partial organs of the human body. Clearly something like embryonic stem cells is being produced in those tumors. And I thought to myself, “If nature can do this, we can do it. There must be simple technological alterations we could use in concert with nuclear transfer such that we produced embryonic­-type, pluripotent stem cells, but without producing the unitary organism that is a human embryo.”

TR: Does ANT produce truly pluri­potent stem cells?

WH: [MIT’s] Rudy Jaenisch got pluri­potent cells. He injected some of the cells into living mice, and they formed tumors with all the tissue types in them. So yes, it works. The next step with altered nuclear transfer is to study it in primates. If it works in primates, specifically in rhesus macaques, then we can proceed with pretty good confidence, but also caution, in working with human cells.

0 comments about this story. Start the discussion »

Credit: Andrew Nagata

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me